Prolia

April 21, 2026

Defending the Skeleton After CDK4/6 Inhibition

The drugs keeping breast cancer at bay may be quietly destroying the bones that hold your patient upright. Here's the molecular logic — and the clinical playbook — behind one of oncology's most critical balancing acts.
Defending the Skeleton After CDK4/6 Inhibition
This website uses cookies to improve your experience. By using this website you agree to our Cookie Policy.
Read more